THYMOSIN BETA-4 FRAGMENT / TISSUE-REPAIR RESEARCH
TB-500 is an acetylated seven-amino-acid fragment corresponding to residues 17–23 of thymosin beta-4. Direct evidence specific to TB-500 is limited, and findings from full-length thymosin beta-4 should not be treated as interchangeable evidence.
PRIMARY RESEARCH AREAS
Actin regulation and cytoskeletal biology; cell migration; tissue-repair signaling; angiogenesis research; inflammatory signaling; wound-healing and regenerative biology
EVIDENCE LEVEL
Direct evidence specifically attributable to TB-500 is limited. A larger scientific literature exists for thymosin beta-4, including preclinical research and some human investigation of specific thymosin beta-4 formulations, but this is not automatically direct evidence for TB-500.
TB-500 is commonly discussed in relation to thymosin beta-4 biology, but compound identity and formulation distinctions are essential when interpreting the literature. Related thymosin beta-4 research provides biological context rather than direct clinical evidence for TB-500.
TB-500 is a research compound associated with a short thymosin beta-4-related sequence. Endogenous thymosin beta-4, experimentally studied thymosin beta-4 formulations, and TB-500 should not be treated as interchangeable entities. Much of the interest surrounding TB-500 derives from biological research involving thymosin beta-4 pathways, but clinical effects demonstrated with another thymosin beta-4 formulation have not thereby been demonstrated with TB-500.
Scientific interest in thymosin beta-4 biology has included tissue repair, cell migration, actin dynamics, angiogenesis, inflammatory processes, wound healing, and tissue-injury models. These findings span cellular research, animal models, and selected human thymosin beta-4 investigations. Each evidence category should be identified separately rather than collapsed into direct TB-500 evidence.
Overlapping research areas provide a rationale for studying the constituents together, but they do not establish additive or synergistic effects.
Evidence for GLOW should be read as separate GHK-Cu, BPC-157, and thymosin beta-4 / TB-500 contexts rather than as evidence for a single tested product. The concise evidence matrix below summarizes the cellular, preclinical, and human landscape.
A major limitation is the scarcity of direct controlled human research specifically evaluating TB-500. Unresolved questions include pharmacokinetics of specific formulations, dose-response relationships, long-term safety, human efficacy, formulation equivalence, tissue-specific effects, potential adverse effects, and whether findings involving thymosin beta-4 translate to TB-500. Related thymosin beta-4 research cannot automatically establish safety or efficacy for TB-500.
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733–738. PMID: 22962027. DOI: 10.1002/dta.1402. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103–2105. PMID: 14500546. DOI: 10.1096/fj.03-0121fje. References and claims are limited to evidence that can be verified for the exact compound, formulation, or biological system described.
References were checked against supplied and PubMed-indexed primary-source records.
Evidence involving individual constituents should be interpreted according to the exact compound, formulation, route, population and endpoint studied. Controlled human evidence specifically evaluating the combined 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 formulation has not been established.
CELLULAR / IN-VITRO EVIDENCE
Cellular research involving thymosin beta-4, actin regulation, cellular migration, angiogenesis, and tissue-repair pathways is primarily mechanistic evidence. It should not be interpreted as proof of clinical outcomes with TB-500.
ANIMAL / PRECLINICAL EVIDENCE
Thymosin beta-4 preclinical research includes tissue injury, repair, inflammation, wound healing, and cardiovascular or tissue-injury models. This is preclinical evidence and is not direct TB-500 human evidence.
Human studies of thymosin beta-4 or specific thymosin beta-4 formulations should be distinguished from studies specifically evaluating TB-500. Direct controlled human TB-500 evidence remains sparse or absent in the profile’s source record.
Established biological findings: thymosin beta-4 biology is linked to actin and cellular migration processes. Preclinical findings: relevant effects are demonstrated primarily in cellular or animal research. Human thymosin beta-4 evidence: some studies involve identifiable thymosin beta-4 formulations. TB-500-specific evidence: only findings directly demonstrated with TB-500 should be attributed to TB-500. Still under investigation: human efficacy, long-term safety, formulation equivalence, injury recovery, musculoskeletal outcomes, athletic recovery, and other proposed applications lacking sufficient direct controlled evidence.
Safety data from endogenous thymosin beta-4 or another formulation do not establish the safety of TB-500. Direct human safety evidence for TB-500 specifically is limited, and no dosing or administration conclusions are drawn here.
Major gaps include lack of extensive controlled human TB-500 trials, compound and formulation identity, extrapolation from thymosin beta-4, long-term safety, pharmacokinetics, dose-response research, human musculoskeletal outcomes, standardized formulations, and reproducibility. Biological plausibility and related-compound evidence are not equivalent to demonstrated clinical efficacy.
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, compound identity, thymosin beta-4 biology, preclinical evidence, human evidence, safety evidence, and distinction between TB-500-specific findings and research involving thymosin beta-4 or other formulations.